NVIDIA expands BioNeMo platform with new foundation models and microservices for AI-powered Drug Discovery

The most recent NVIDIA BioNeMo foundation models can help drug discovery groups design drug molecules virtually. [Credit: NVIDIA]

NVIDIA is putting the power of generative AI for drug discovery into the hands of more pharmaceutical and biotech companies with an expanded collection of AI models and flexible deployment options. More than 100 firms are already using the company’s biomolecular BioNeMo platform to accelerate the development of therapeutics.

“For the first time in history, we can represent the world of biology and chemistry in a computer, making computer-aided drug discovery possible,” said Kimberly Powell, NVIDIA VP of healthcare, in a press briefing. “By helping healthcare companies easily build and manage AI solutions, we’re enabling them to harness the full power and potential of generative AI.”

The latest additions to BioNeMo, announced today at NVIDIA G…

Read more
  • 0

Eversana’s AWS alliance aims to cut red tape in pharma regulatory paperwork

In July, the life sciences services company Eversana revealed it was partnering with AWS to tap generative AI (gen AI) for pharma and other life science customers. It aimed to “pharmatize” gen AI, as the company put it then. Now, the company has revealed the first technology from that partnership – a regulatory review automation system using natural language processing and gen AI services on the AWS platform.

To arrive at its first area of focus, the company considered use cases that were “really practical,” offering “great opportunities for efficiency gains,” but without high risk to patients or healthcare professionals, said Scott Snyder, Eversana’s chief digital officer. The company used a version of the three R’s — responsibility, reliability and ROI. The first chiefly involves “making sure you really understand this is something you’re going to take ownership of, be accountable for, and do it in the right way,” Snyder said. Eversana …

Read more
  • 0